ANIX — Anixa Biosciences Share Price
Last trade - 00:00- $99.53m
- $74.73m
- $0.21m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.05 | ||
| Price to Tang. Book | 4.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 473.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.88% | ||
| Return on Equity | -41.01% | ||
| Operating Margin | -5744.76% | ||
Financial Summary
| Year End 31st Oct | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.25 | n/a | 0.51 | n/a | 0.21 | n/a | n/a | -28.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
Directors
- Amit Kumar CHM (56)
- Michael Catelani CFO (54)
- Lewis Titterton LED (76)
- Arnold Baskies IND (71)
- Emily Gottschalk IND (60)
- Last Annual
- October 31st, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- November 5th, 1982
- Public Since
- October 7th, 1983
- No. of Shareholders
- 312
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 31,899,800
- Address
- 3150 Almaden Expy Ste 250, SAN JOSE, 95118
- Web
- https://www.anixa.com/
- Phone
- +1 4087089808
- Auditors
- Haskell & White LLP
Upcoming Events for ANIX
Similar to ANIX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 19:02 UTC, shares in Anixa Biosciences are trading at $3.12. This share price information is delayed by 15 minutes.
Shares in Anixa Biosciences last closed at $3.12 and the price had moved by -37.1% over the past 365 days. In terms of relative price strength the Anixa Biosciences share price has underperformed the S&P500 Index by -47.65% over the past year.
The overall consensus recommendation for Anixa Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Anixa Biosciences does not currently pay a dividend.
Anixa Biosciences does not currently pay a dividend.
Anixa Biosciences does not currently pay a dividend.
To buy shares in Anixa Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.12, shares in Anixa Biosciences had a market capitalisation of $99.53m.
Here are the trading details for Anixa Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ANIX
Based on an overall assessment of its quality, value and momentum Anixa Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Anixa Biosciences is $12.00. That is 284.62% above the last closing price of $3.12.
Analysts covering Anixa Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.44 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anixa Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -15.37%.
As of the last closing price of $3.12, shares in Anixa Biosciences were trading -13.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Anixa Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Anixa Biosciences' management team is headed by:
- Amit Kumar - CHM
- Michael Catelani - CFO
- Lewis Titterton - LED
- Arnold Baskies - IND
- Emily Gottschalk - IND